Foresite Capital Fund IV, L.P. - 31 Mar 2025 SCHEDULE 13G/A Report for Lyell Immunopharma, Inc. Common Stock, par value $0.0001 (LYEL)

Filing Manager
Foresite Capital Fund IV, L.P.
Reporting Manager
James B. Tananbaum
Security
Lyell Immunopharma, Inc. Common Stock, par value $0.0001
Symbol
LYEL
Shares outstanding
295,237,957 shares
Disclosed Ownership
27,161,892 shares
Ownership
9.2%
Form type
SCHEDULE 13G/A
Filing time
15 May 2025, 16:04:57 UTC
Date of event
31 Mar 2025
Previous filing
14 Feb 2025
SEC
View on sec.gov

Reporting Managers (7)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Foresite Capital Fund IV, L.P. 5.4% 16,007,999 16,007,999 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management IV, LLC 5.4% 16,007,999 16,007,999 0 /s/ James Tananbaum James Tananbaum, Managing Member
Foresite Capital Fund V, L.P. 2.8% 8,133,047 8,133,047 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Management V, LLC 2.8% 8,133,047 8,133,047 0 /s/ James Tananbaum James Tananbaum, Managing Member
Foresite Capital Opportunity Fund V, L.P. 1% 3,020,846 3,020,846 0 /s/ James Tananbaum James Tananbaum, Managing Member of the General Partner
Foresite Capital Opportunity Management V, LLC 1% 3,020,846 3,020,846 0 /s/ James Tananbaum James Tananbaum, Managing Member
James B. Tananbaum 9.2% 27,161,892 27,161,892 0 /s/ James Tananbaum James Tananbaum